AEterna Zentaris
Echelon Biosciences granted U.S. patent for PI3-K, reinforcing its leadership in cancer assays
Published in Law and Health Weekly, July 22nd, 2006
This patent reinforces Echelon's leadership position in the phospholipids research space, is the first patent allowance of its kind, and strengthens the oncology synergy within Echelon's parent company, AEterna Zentaris (AEZS).
PI3-K is a key cellular enzyme and is often altered in diseases, leading to abnormal cell growth in cancer and pathological cellular response in inflammation. Considerable research is being done to determine its importance and potential as a target for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Addenbrooke's Hospital, Cambridge, U.K.
Breast lesion classification system for magnetic resonance screening has been evaluated - Fitch Ratings
Fitch revises Schering-Plough Corp.'s Rating Outlook to Stable, affirms 'A-/F2' - Groningen University, Netherlands
More patients switch to another proton pump inhibitor after omeprazole patent expiry - Healthcare Costs
A new survey released finds that Medicare prescription drug plans are paying pharmacists promptly - Intact Medical
Intact receives key patent for technology behind its Breast Lesion Excision System - Johns Hopkins University, U.S.
Neutralizing antibodies do not mediate suppression of HIV in elite suppressors - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
